Successful sodium thiosulphate treatment for recurrent calcium urolithiasis.
Thirty-four idiopathic rapid calcium stone formers (24 male/10 female) were studied. Their ages ranged from 20 to 60 years (40 +/- 11) and all had good renal function. The trial comprised two consecutive periods of 3 years and 4 years duration respectively. In the first (control period), the patients were maintained on a customary diet with an adequate fluid intake sufficient to produce about 2 liters of urine daily. In the second (treatment period), they received a similar diet plus 20 mmol of sodium thiosulphate daily. New stone development fell from 100 in the control period to 15 in the treatment period, corresponding to a rate of 0.98 and 0.11 per year (p less than 0.001). It is suggested that the benefit from sodium thiosulphate results from calcium thiosulphate formation in urine, a salt with a molar solubility of 250 to 100.000-fold greater than that of other urinary calcium salts.
D000328:Adult; D002118:Calcium / Q000378:metabolism* / Q000652:urine; D017610:Calcium Compounds; D002129:Calcium Oxalate / Q000652:urine; D002130:Calcium Phosphates / Q000652:urine; D002133:Calcium Sulfate / Q000652:urine; D002951:Citrates / Q000652:urine; D019343:Citric Acid; D002986:Clinical Trials as Topic; D004032:Diet; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008274:Magnesium / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010758:Phosphorus / Q000378:metabolism; D012008:Recurrence; D012995:Solubility; D013885:Thiosulfates / Q000627:therapeutic use* / Q000652:urine; D013997:Time Factors; D014545:Urinary Calculi / Q000188:drug therapy* / Q000517:prevention & control
D017610:Calcium Compounds; D002130:Calcium Phosphates; D002951:Citrates; D013885:Thiosulfates; D002129:Calcium Oxalate; D010758:Phosphorus; D019343:Citric Acid; C044674:calcium thiosulfate; C017717:sodium thiosulfate; D008274:Magnesium; D002118:Calcium; D002133:Calcium Sulfate